REACH

14 April 2025

Cizzle Biotechnology Holdings plc

("Cizzle", "Cizzle Biotechnology", or the "Company")

Launch of New Website

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to announce that it has launched its new corporate website, which can be viewed at:

https://cizzlebiotechnology.com

Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:

"I am delighted to announce that our new website is now live for all stakeholders including shareholders, investors and customers, to access a wide range of information and latest news on the Company's status and products. This is an exciting time for Cizzle Biotechnology as we continue to finalise our near term regulatory and launch plans in the USA as part of our global strategy to bring the non-invasive, cost effective, CIZ1B Biomarker test for early-stage lung cancer to market.  The new website is designed to provide a user-friendly interface for all stakeholders and we look forward to adding new content as part of an enhanced communication strategy to support the Company's growth."

Enquiries:

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered into commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care.  Cizzle was admitted to trading on the Main Market of the London Stock Exchange in May 2021. 

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.